Drug eluting stents in adults with acute coronary syndrome: a review of the clinical effectiveness, safety and guidelines
CADTH
Record ID 32012000701
English
Authors' recommendations:
During the first year after implantation, drug-eluting stent (DES) use in ACS patients, particularly STEMI, was associated with a significant reduction in revascularization and recurrent MI, without increased risk of mortality or stent thrombosis. However, in long-term follow-up (beyond 2 years), DES was associated with an increased risk of stent thrombosis compared with bare metal stents. Results for revascularization were similar for patients with unstable angina/NSTEMI, but this evidence was limited to three observational studies.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf//htis/aug-2012/RC0377%20DES%20in%20ACS%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Acute Coronary Syndrome
- Drug-Eluting Stents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.